• Skip to main content
  • Skip to header right navigation
  • Skip to site footer
Endogenex

Endogenex

Bringing New Energy to the Treatment of Type 2 Diabetes

  • T2D
  • ReCET
  • Patients
  • Clinical Providers
  • About Us
    • News
    • Contact
  • ReCET Study

7News Australia report: Clinical study evaluating technology to treat Type 2 Diabetes being expanded

Type 2 Diabetes affects 1.8 million people in Australia but a new clinical study by Endogenex is looking to change that.

In a recent broadcast by 7News Australia, Dr. Adrian Sartorretto describes the basis of the trial, “It offers the (opportunity) of improving blood sugar control while also reducing the medication burden on patients.”

While in the early stages of the study, Australia is one of three study countries (also being done in Netherlands and U.S.) with patients participating in a clinical study evaluating the ReCET procedure to treat Type 2 Diabetes.

Watch full broadcast. (Please note, this is an international link and may not work on all browsers)

Previous Post:Clinical study participant with Type 2 Diabetes shares his story
Next Post:Endogenex™ Appoints Medical Device Executive, Stacey Pugh, Chief Executive OfficerEndogenex

* Caution: Exclusively a clinical investigational device. Limited by federal (or United States or similar) law to investigational use. Not for sale in any geography.

Please refer to your physician for additional information on the ReCET Procedure, ReCET System, and related risks.

Endogenex, Inc.
13755 1st Avenue North #100
Plymouth, MN 55441
+1 763-251-6820
info@endogenex.com

References

Terms of Use

Privacy Policy

Cookie Policy

EndogenexTM and ReCETTM are registered trademarks of Endogenex, Inc. in the United States and other countries. Copyright © 2025 Endogenex, Inc. All rights reserved.

  • LinkedIn
  • X
  • Vimeo